Navigation

R&D spending makes strong gains

Spending on research and development among Swiss companies has climbed 20 per cent to $20.9 billion (SFr24.1 billion), according to a strategy consulting firm.

This content was published on October 21, 2008 - 16:45

A statement released on Tuesday by management consultants Booz & Company said surveyed companies allocated 7.9 per cent of total sales for R&D expenditures, up from 7.3 per cent over the previous year.

Basel-based pharmaceutical firm Roche led Switzerland's strong performance, placing 8th and increasing spending by 16 per cent to $6.9 billion. Rival Novartis ranked 11th and the food giant Nestlé placed 75th.

"Swiss industry is reinforcing the conviction that investing in innovation is of enormous importance for the long-term success of companies," said Carlos Ammann, Booz & Company's managing director in Zurich.

Worldwide, R&D spending grew ten per cent, while in Europe it grew 12 per cent. China and India posted 22 per cent increases.

Booz & Company said that the downturn in global markets could curtail spending but noted that countercyclical investment in R&D usually paid off.

The consultancy said that 90 per cent of 1,000 top companies surveyed pursued research outside their own home countries.

This article was automatically imported from our old content management system. If you see any display errors, please let us know: community-feedback@swissinfo.ch

Comments under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

Share this story

Join the conversation!

With a SWI account, you have the opportunity to contribute on our website.

You can Login or register here.